MCP
BSX icon

Meridiem Capital Partners’s Boston Scientific BSX Stock Holding History

Meridiem Capital Partners’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$9.76M – 77
2025
Q3 		$9.76M Buy
+100,000
New +$10.4M 0.62% 50

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Meridiem Capital Partners's BSX Position: Q1 2026 in Review

Meridiem Capital Partners sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 608,758 shares — an estimated $58M sold.

Meridiem Capital Partners first reported a position in BSX in Q1 2025 and held it in 4 quarters. The position peaked at $70.3M in Q3 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Meridiem Capital Partners reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
  • Meridiem Capital Partners sold 608,758 Boston Scientific shares in Q1 2026, an estimated $58M.
  • Meridiem Capital Partners first reported a position in Boston Scientific in Q1 2025 and held it in 4 quarters.
  • Meridiem Capital Partners's Boston Scientific position peaked at $70.3M in Q3 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Meridiem Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.